Evofem Reports First Quarter 2026 Financial Results and Provides Business Update

Evofem reported Q1 2026 net sales of $0.9 million, a 6.5% increase year-over-year, driven by higher wholesale acquisition costs and favorable gross-to-net ratios for PHEXX and SOLOSEC. The company posted a net loss of $5.5 million ($0.04 per share), compared to net income of $1.0 million in the prior year period. Total operating expenses declined to $5.5 million from $6.1 million, aided by a one-time $5.6 million reduction in R&D expenses from settling trade payables. Balance sheet metrics highlight significant liquidity risk: cash and equivalents stood at $1.5 million against $78.8 million in current liabilities, resulting in a stockholders' deficit of $77.6 million.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.